期刊
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
卷 19, 期 11, 页码 685-686出版社
NATURE PORTFOLIO
DOI: 10.1038/s41575-022-00686-8
关键词
-
Antibodies targeting tumour necrosis factor have improved the treatment of paediatric inflammatory bowel disease. Understanding pharmacokinetics and therapeutic drug monitoring has led to increased efficacy and durability of response. Primary non-response is more common in ulcerative colitis, emphasizing the need for alternative biologic agents and oral small molecules.
Antibodies targeting tumour necrosis factor have substantially advanced the treatment of paediatric inflammatory bowel disease. Understanding pharmacokinetics and therapeutic drug monitoring has led to increased efficacy and durability of response. Primary non-response is more common in ulcerative colitis than in Crohn's disease, highlighting the need for alternative biologic agents and oral small molecules.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据